There is a newer version of the record available.

Published July 3, 2023 | Version v1
Peer review Restricted

Calcium Electrochemotherapy for Tumor Eradication and the Potential of High-Frequency Nanosecond Protocols

  • 1. State Research Institute Centre for Innovative Medicine, Department of Immunology, Vilnius, Lithuania
  • 2. State Research Institute Centre for Innovative Medicine, Department of Biomodels
  • 3. Faculty of Electronics, Vilnius Gediminas Technical University, Vilnius, Lithuania

Description

Abstract: Calcium electroporation (CaEP) is an innovative approach to treating cancer, involving the internalization of supraphysiological amounts of calcium through electroporation, which leads to cell death. CaEP enables replacement of the usage of chemotherapeutics (e.g., bleomycin). Here we present a standard microsecond (μsCaEP) and novel high-frequency nanosecond protocols for calcium electroporation (nsCaEP) for the elimination of carcinoma tumors in C57BL/6J mice. We show the efficacy of CaEP to eliminate tumors and increase their survival rates in vivo. The antitumor immune response after the treatment was observed by investigating immune cell populations in tumors, spleens, lymph nodes, and blood as well as assessing antitumor antibodies. CaEP treatment resulted in an increased percentage of CD4⁺ and CD8⁺ central memory T cells and decreased tumor-associated and splenic myeloid-derived suppressor cells (MDSC). Also, increased levels of antitumor IgG antibodies after CaEP treatment were detected. The experimental results demonstrated that the administration of CaEP led to tumor growth delay, increased survival rates, and stimulated immune response, indicating a potential synergistic relationship between CaEP and immunotherapy.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:

Article supplementary file

You are currently not logged in. Do you have an account? Log in here